OIG Raises Reimbursement Policy Questions For Avastin And Lucentis In Wake Of CATT Findings
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysis of money spent on the treatments for wet age-related macular degeneration offers an argument for least costly alternative policy as a way of cutting health care spending.
You may also be interested in...
Lucentis vs. Avastin Cost Debate Resurfaces With Release Of Medicare Payment Data
Ophthalmologists are among the highest billing specialties listed in the Medicare Part B physician payment data, with Genentech’s Lucentis a strong driver of cost.
Former CMS Officials Call For Cost To Be Factored Into Coverage Decisions
Four former CMS officials are recommending authority to use cost-related analysis and policies be added to the tools the agency can use as a means of improving the quality and efficiency of Medicare.
Former CMS Officials Call For Cost To Be Factored Into Coverage Decisions
Four former CMS officials are recommending authority to use cost-related analysis and policies be added to the tools the agency can use as a means of improving the quality and efficiency of Medicare.